American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

BioAtla, Inc. (BCAB)

$1.71 +39.02% NASDAQ: BCAB · 15-min delayed

SAN DIEGO, California
Public · NASDAQ: BCAB
41 employees

Visit website Follow

$5.6MMarket cap

$300.0KRevenue · FY2021

-$59.6MNet income

41Employees

BCABNASDAQ

2020IPO

About BioAtla, Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: BCAB
Employees: 41
IPO date: Dec 16, 2020
Headquarters: 11085 TORREYANA ROAD
SAN DIEGO, California 92121
Phone: 858-558-0708
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: BCAB Nasdaq
SEC CIK: 1826892
EIN: 851922320
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show BioAtla, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/bioatla-inc/"><img src="https://americancompanies.com/badge/bioatla-inc.svg" alt="BioAtla, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow BioAtla, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2021: $300.0K
Net income: -$59.6M
Total assets: $13.8M
Market cap: $5.6M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: BCAB

$1.71 +39.02%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.08 $61.00

52-week range

Market cap: $5.6M
Shares outstanding: 3.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Dec 16, 2020

BioAtla, Inc. (BCAB) Stock Price

Reported a net loss of $59.6M in FY2021.
Trading 97% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review BioAtla, Inc..

Write a review

Newsroom

News about BioAtla, Inc.

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) GlobeNewswire Inc. · 2025-12-31 · positive BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing GlobeNewswire Inc. · 2025-11-21 · positive BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society GlobeNewswire Inc. · 2025-10-23 · positive BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 GlobeNewswire Inc. · 2025-10-03 · positive BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 GlobeNewswire Inc. · 2025-08-04 · neutral BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress GlobeNewswire Inc. · 2025-07-03 · positive

News & sentiment via Polygon.io

FAQ

BioAtla, Inc.: frequently asked questions

Is BioAtla, Inc. an American company?

BioAtla, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is BioAtla, Inc. headquartered?

BioAtla, Inc. is headquartered in San Diego, California, United States.

Is BioAtla, Inc. publicly traded?

Yes — BioAtla, Inc. is a publicly traded company. Its stock trades under the ticker symbol BCAB on the NASDAQ.

What does BioAtla, Inc. do?

BioAtla, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore